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E-mail address: ndarz@certh.gr (N. Darzentas).Motivation: PubMed is the most widely used database of biomedical literature. To the detriment of the
user though, the ranking of the documents retrieved for a query is not content-based, and important
semantic information in the form of assigned Medical Subject Headings (MeSH) terms is not readily pre-
sented or productively utilized. The motivation behind this work was the discovery of unanticipated
information through the appropriate ranking of MeSH term pairs and, indirectly, documents. Such infor-
mation can be useful in guiding novel research and following promising trends.
Methods: A web-based tool, called MeSHy, was developed implementing a mainly statistical algorithm.
The algorithm takes into account the frequencies of occurrences, concurrences, and the semantic similar-
ities of MeSH terms in retrieved PubMed documents to create MeSH term pairs. These are then scored
and ranked, focusing on their unexpectedly frequent or infrequent occurrences.
Results: MeSHy presents results through an online interactive interface facilitating further manipulation
through ﬁltering and sorting. The results themselves include the MeSH term pairs, along with MeSH cat-
egories, the score, and document IDs, all of which are hyperlinked for convenience. To highlight the appli-
cability of the tool, we report the ﬁndings of an expert in the pharmacology ﬁeld on querying the
molecularly-targeted drug imatinib and nutrition-related ﬂavonoids. To the best of our knowledge,
MeSHy is the ﬁrst publicly available tool able to directly provide such a different perspective on the com-
plex nature of published work.
Implementation and availability: Implemented in Perl and served by Apache2 at http://bat.ina.certh.gr/
tools/meshy/ with all major browsers supported.
 2011 Elsevier Inc. All rights reserved.1. Introduction
The increasing rate of publications entering biomedical litera-
ture databases, in conjunction with their differential source of pro-
duction (clinical, pharmacological and genetic or genomic), make
the process of relevant knowledge extraction difﬁcult and time-
consuming even for specialists. Furthermore, fast, accurate, reliable
and user-friendly retrieval of biomedical information is in increas-
ing demand for most disciplines in health-related areas (e.g. drug
discovery and delivery, diagnosis and therapy in clinical practice,
clinical translation of genomics data). Thus, it has become impera-
tive to develop automated or semi-automated text-mining tools
that are efﬁcient and effective in extracting relevant information
applicable in medicine, pharmacy and biology [1]. The same tools
are critical in highlighting important associations between disease
pathogenesis, drugs and their pharmacodynamic or pharmacoki-ll rights reserved.netic parameters of action, (including drug interactions or adverse
drug reactions), and their molecular targets (e.g. genes, genetic
polymorphisms, proteins, receptors, drug metabolizing enzymes
and transporters) [2–5]. However, upon searching the biomedical
literature, critical connections within and across the various
sources of information are often lost.
PubMed is by far the most popular gateway for access to bio-
medical literature. Despite several algorithms used by the PubMed
retrieval system (like [6,7]), its effectiveness and impact on re-
search is heavily dependent on the query itself. Study [8] describes
methods to facilitate the formulation of precise queries using more
relevant terms, showing that queries are usually up to three terms
long, while study [9] indicates that the use of four to ﬁve terms is
most likely to result in reading the abstracts of the retrieved titles.
Similarly, many questions go unanswered due to lack of skills in
formulating the necessary queries [10].
Another characteristic of the PubMed document retrieval sys-
tem is that the semantic information contained in the Medical Sub-
ject Headings (MeSH) terms [11] is not readily presented to the
Fig. 1. An example of MeSH hierarchy. Inside the brackets is the number that indicates the location of each MeSH term in the hierarchy.
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for indexing and annotating PubMed documents. According to [12]
an ontology deﬁnes a set of representational primitives with which
to model a domain of knowledge or discourse. The MeSH ontology
is a structured vocabulary of semantically related terms, built for
facilitating computational tasks. The more general MeSH terms ap-
pear at the top of the hierarchy whereas more speciﬁc terms ap-
pear at the bottom (Fig. 1). In PubMed, MeSH terms are manually
assigned to each document by indexers (biomedical subject spe-
cialists) based on the context of the whole document and not only
the abstract and/or the title. Thus, they contain high-density infor-
mation from the whole document which may not be inferred from
the title or the abstract that PubMed returns.
The importance of MeSH terms in knowledge discovery has
been widely recognized and several tools have been based on their
utilization. GoPubMed [13] is a system that addresses the issue of
clearly presenting to the end-user the semantic information from
MeSH terms through extensive use of them (along with Gene
Ontology terms) for the presentation and analysis of the results
of a PubMed query. In MiSearch [14] MeSH terms are used to build
statistical models while in MScanner [15] and in Suomela and And-
rade [16] they are used to create the training sets for classiﬁers.
Also, Zhu et al. [17] and Struble and Dharmanolla [18] describe a
method to enhance document clustering by using MeSH term
semantic similarity. Furthermore, in our previous work [19] we
have shown that the information contained in MeSH terms is
highly correlated with the information contained in the title and
abstract of each document and can therefore facilitate document
classiﬁcation and clustering.
MeSH term concurrence has been used as early as 1989 [20] for
helping physicians to explore biomedical literature relevant to
hepatological patient records and in [21] for obtaining medical
knowledge via automated analysis of literature and using it to
build medical knowledge bases. The MeSHMap tool [22] is a tool
similar to GoPubMed which uses only MeSH terms and allows
the user to manually explore term concurrences. An important
semi-automated tool is also Arrowsmith [23] which uses MeSH
term concurrence in order to associate two different sets of Pub-
Med articles. Another approach used speciﬁcally for PubMed doc-
uments is sentence-level concurrence of query keywords used in
Relemed [24]. FACTA [25] is a text search engine speciﬁc for MED-
LINE abstracts that uses concurrence statistics and MeSH terms,
along with other concepts from UniProt [26], KEGG [27], etc. in or-
der to rank retrieved information. Finally, a recent addition is
Epiphanet [28], an interactive knowledge discovery system that al-
lows end-users to explore relations between concepts extracted
from biomedical literature.
Signiﬁcant efforts are being made to personalize information re-
trieval and ranking processes to assist the users in getting the
information they need [29]. To accomplish this, methods eitherhave to know the user’s needs or provide customization for as
many users as possible, both tasks being hard. Methods outlined
above do indeed offer solutions towards both – e.g. Epiphanet
not only adapts to the user by offering related concepts of the ini-
tial query, but also interactively allows for exploration of the
resulting information.
However, there currently does not appear to be a system that
directly promotes (scores higher than others) statistically unantic-
ipated information through pairing of MeSH terms. This last point
has been the motivation behind the development of MeSHy. That
is, how to discover unusual or unanticipated information contained
in MeSH term pairs and their relevant PubMed documents that
usually remain out of reach of the average user due to the low
date-based ranking of PubMed. Since the MeSH terms are essen-
tially carriers of documents’ information, the key idea for address-
ing the research question was to locate and reveal documents that
contain unusually frequent occurrences of MeSH term pairs. Me-
SHy is a system for statistically scoring and ranking MeSH term
pairs from a simple user query to PubMed. The tool is freely avail-
able as a web application.
In the following sections, we ﬁrst describe the different stages
of the methodology in detail, we then include an application report
from an expert group in pharmacology, and ﬁnally we discuss
implications, possible applications, limitations, and future plans.2. Methodology
In summary, MeSHy is an implementation of an algorithm that
extracts the MeSH terms from the retrieved documents, ﬁlters
them excluding the trivial ones and then probabilistically scores
and ranks pairs of MeSH terms derived from each document. Indi-
rectly, the scored MeSH term pairs are used to rank the documents
themselves. The ﬁltering is performed in two stages and its pur-
pose is to keep the most informative and descriptive MeSH terms
of the query.
The main stages of the methodology are (also depicted in
Fig. 2):
2.1. Stage i
In Stage i a query is submitted to the PubMed retrieval system
and the relevant documents are retrieved.
2.2. Stage ii
Stage ii involves the extraction of the MeSH terms, and option-
ally of the chemical terms (hereafter implied under MeSH terms),
from the documents and the construction of all possible MeSH
term pairs of each document. Chemical terms are part of the MeSH
Fig. 2. The stages of the MeSHy methodology.
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concepts for PubMed documents. Formally, from a set of docu-
ments D the method constructs a set of MeSH terms M containing
all the MeSH terms in the documents and a set of MeSH term pairs
G. We assume that two MeSH terms are considered as a pair if and
only if they occur together in any of the documents of the set D. By
considering only pairs derived from each document we avoid the
construction of MeSH term pairs merely by chance and thus the
creation of potentially uncorrelated and misleading information.2.3. Stage iii
Let n = |D| denote the total number of documents retrieved by
the query. Also, we denote by fm the number of appearances of a
certain MeSH term m in the set of the retrieved documents D.
The ratio of fm divided by the total number of documents in D is de-
noted by P(m; D). Hence, for every MeSH term the procedure
calculates:
Pðm;DÞ ¼ fm
n
ð1Þ
Note that given the set D and the fact that a MeSH term either
appears only once in a document or does not appear at all, formula
(1) provides an estimation of the probability to ﬁnd a speciﬁcMeSH term m within the body of documents D retrieved by a
query. We emphasize that this notion is different from the notion
of ‘‘term frequency’’ [30], used in the ﬁeld of Information Retrieval,
which is the normalized number of occurrences of a word in a spe-
ciﬁc document and expresses the importance of the word within
the particular document.
2.4. Stage iv
MeSH terms are ﬁltered in order to keep those that are most
informative and potentially useful for the speciﬁc set of documents
D. The basic assumption is that the terms that have almost the
same probability of being observed within the results of a query
and also in the entire PubMed database (excluding the results of
the query) do not contain important information speciﬁc to the
documents related to the query. We denote by S the set of all doc-
uments in PubMed and with N = |S| the size of S. Also, we denote by
Fm the number of appearances of a certain MeSH term m in the set
of all documents S in PubMed. Then we calculate the ratio
Pðm; S DÞ ¼ Fm  fm
N  n ð2Þ
as an estimation of the probability of the occurrence of MeSH term
m within the set S  D, i.e. the set of documents of PubMed that do
not belong in the set of query documents D. This ratio is calculated
with information from the MEDLINE Baseline Repository system.
The MeSH terms are ﬁltered based on the ratio
Pðm;DÞ
Pðm; S DÞ ; ð3Þ
Ratio (3) measures the odds of observing a speciﬁc MeSH term
m ‘‘inside’’ the query against of observing it ‘‘outside’’ the query.
When the ratio is close to one, i.e. when the probabilities are al-
most equal, the MeSH term is not considered informative for the
query and can be ﬁltered using a predeﬁned threshold to check
equality. The ratio in formula (3) resembles the ‘‘F-divergence’’
function which is used in Information Retrieval for a different pur-
pose, i.e. to measure the similarity between two documents based
on the distributions of their words [31].
Consequently, after the ﬁltering, a subset of the original MeSH
terms M0 # M and the corresponding subset of their pairs G0 # G
are obtained.
2.5. Stage v
This stage involves the scoring of the remaining (i.e. non-ﬁl-
tered) MeSH term pairs. The score depends on estimations of cer-
tain probabilities. A pair of MeSH terms m1 and m2 is denoted by
g e G0. Also, the estimated probabilities of ﬁnding the MeSH terms
m1 and m2 and their pair g in the query documents set D are de-
noted by P(m1; D), P(m2; D) and P(g; D). The score of the pair g is
then calculated by the following formula:
sðgÞ ¼ log Pðg;DÞ
Pðm1;DÞPðm2;DÞ
 
; ð4Þ
The rationale behind (4) is based on the well-known deﬁnition
of independence in probability theory. Two events are independent
when the probability of their concurrence is equal to the product of
the probabilities of occurrences of each one. Therefore, departure
from equality means that the events are dependent. So, the score
is positive for MeSH term pairs which have a higher observed prob-
ability than the one theoretically computed if the MeSH terms of
the pair were independent, and is negative in the opposite case.
Both positive, i.e. observed more than expected, and negative, i.e.
observed less than expected, scores indicate a MeSH term pair with
922 T. Theodosiou et al. / Journal of Biomedical Informatics 44 (2011) 919–926probabilistically unanticipated information, whereas a score
around zero indicates a pair with more or less expected, and pos-
sibly already known, information.
It must be noted that in order to avoid pairs that describe the
same biomedical concept, we apply ‘‘semantic pruning’’ by ﬁltering
out pairs that are semantically close. We calculate a similarity
score based on the position of each MeSH term of the pair on the
MeSH tree [32]. The semantic score sim takes values between 0
and 1, where a value of 1 signiﬁes total coincidence of the terms
and a value of 0 the opposite.
The ﬁnal score for each MeSH term pair is:
s0ðgÞ ¼ sðgÞ  ð1 simÞ ð5Þ2.6. Stage vi
Finally, the MeSH term pairs are sorted according to the
descending order of their scores and presented to the user in an
interactive HTML table format which features a Javascript applica-
tion for instantaneous management of columns including ﬁltering
and sorting (Figs. 3 and 4). Next to the name of each MeSH termwe
include, for informational purposes only and inside square brack-
ets, the popularity of the term in the query: terms in the query hav-
ing ratio (1) equal and above to 1% are considered ‘‘popular’’, terms
with ratio (1) equal and below 0.1% are considered ‘‘rare’’, while
the rest of the MeSH terms are considered ‘‘normal’’ – these thresh-
olds are arbitrary and they do not affect the scoring and ranking of
the results.
In order to facilitate further analysis and searching of the re-
sults, we also include the MeSH term categories (Table 1) from
the ontology tree along with the position of each term in the hier-
archy. The deeper this position is in the MeSH tree, the more spe-
ciﬁc it is. Furthermore, the relevant document PMID (PubMed
Document ID) or PMIDs the pair is in, along with their year of pub-
lication and their type (e.g. case report, review, multicenter study,Fig. 3. The top ten (10) pairs of MeSH terms of the online MeSHy report upon querying t
documents it returned. The number of the resulting MeSH term pairs is indicated on the
display or hide. Just above the titles of the columns are the ﬁlters that can be applied to ea
column. The ‘‘PMIDs’’ column contains the PubMed ID(s) of the document(s) containing t
ranking of the speciﬁc document in PubMed, followed by the year of publication.etc.), are added to the output. The user can follow available hyper-
links either of the MeSH terms and connect to the MeSH database
where each term is described, or can visit PubMed through the
PMID and read the document.
MeSHy was implemented using the Common Gateway Interface
(CGI – http://www.w3.org/CGI/) and the Perl programming lan-
guage (http://www.perl.org). The EFetch and ESearch utilities cre-
ated by Oleg Khovayko that are part of the Entrez Programming
Utilities (http://eutils.ncbi.nlm.nih.gov/) are used to query and re-
trieve documents from PubMed. Results are presented using the
HTML Table Filter Generator (http://tableﬁlter.free.fr/).3. Application: a qualitative analysis
3.1. Considerations and methodology
The indirect ranking of the documents obtained by directly
ranking the MeSH term pairs as described in the previous section
is not comparable to other ranking algorithms that focus on the
most relevant documents to a query. Under this perspective, it is
meaningless to evaluate the results of MeSHy quantitatively by
statistical measures of error. In fact, the notion of ‘‘unanticipated
knowledge’’ is not measurable and is basically strongly subjective
and context-dependent. It is therefore a challenge to assess the po-
tential of MeSHy in highlighting unanticipated information to dis-
cover or produce knowledge.
We started facing this challenge by consulting experts. The tool
was demonstrated to a number of collaborating researchers in
medicine, pharmacology, and plant biology who ran queries re-
lated to their research and then they were asked to comment on
the results. During subsequent informal and extensive discussions
they provided useful feedback. The general impression was that
the PubMed documents containing the highest ranking MeSH pairs
were in fact unexpected, in the sense that the research they de-
scribe was novel or divergent from the mainstream research. Inhe term ‘‘imatinib’’. The title of the table includes the query and the total number of
left side, just below the title, whereas on the right one can choose which columns to
ch column, while the column titles are also clickable and allow the user to sort each
he corresponding MeSH term pair. Inside the parenthesis, after the ID, is the default
Fig. 4. Results for MeSH pairs obtained by querying the term ‘‘ﬂavonoids nutrition’’ in MeSHy. Note that the ﬁrst ﬁve MeSH pairs are shown above.
Table 1
The MeSH categories.
No. Category
1 Anatomy [A]
2 Organisms [B]
3 Diseases [C]
4 Chemical and Drugs [D]
5 Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
6 Psychiatry and Psychology [F]
7 Phenomena and Processes [G]
8 Disciplines and Occupations [H]
9 Anthropology, Education, Sociology and Social Phenomena [I]
10 Technology, Industry, Agriculture [J]
11 Humanities [K]
12 Information Science [L]
13 Named Groups [M]
14 Health Care [N]
15 Publication Characteristics [V]
16 Geographicals [Z]
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with rather rare incidents or laboratory studies combining ele-
ments from different scientiﬁc disciplines. All of the users com-
mented that the tool was in fact useful since it highlighted
studies that otherwise would be buried under the usually large
majority of more recent or mainstream research.
Encouraging as the abovementioned comments and discussions
were, they were not speciﬁc. Therefore, the evaluation of MeSHy
was performed by an expert group in the Laboratory of Pharmacol-
ogy, Department of Pharmaceutical Sciences at the Aristotle Uni-
versity of Thessaloniki. In particular, the group consisted of one
Associate Professor and three postgraduate students. Queries (Ta-
ble 2) were based on a recent publication covering both pharmaco-
logical and clinical data of innovative antileukemia therapeutics
[33]. They were also based on the established interest of the Labo-
ratory in the link between pharmaceutical substances and targets
and nutrition. Emphasis was given on assessing the capacity of Me-
SHy to unveil unanticipated knowledge regarding: (a) drug-target
identiﬁcation, (b) pharmacodynamics and pharmacokinetics
parameters, (c) disease and drug delivery issues, (d) adverse drug
reactions data, and (e) drug interactions records. Organizationally,
a ﬁrst meeting was arranged with all involved and headed by the
coordinator of the study aimed at introducing and brieﬂy showing
MeSHy to the evaluation team, taking care not to inﬂuence objec-
tives, feedback or conclusions. The Associate Professor then set the
scientiﬁc objectives as outlined above, and each evaluation teammember worked independently with all queries of Table 2. Several
one-to-one meetings took place between the Associate Professor
and members of the team who required assistance, as is the usual
procedure in a research environment. A ﬁnal meeting provided the
opportunity to all to openly discuss the results of the evaluation,
both on the impact of MeSHy on the evaluation team’s scientiﬁc
perspective, and on the usability and technical issues regarding
the tool itself. Further clariﬁcations to speciﬁc members of the
evaluation team were given during the development of MeSHy.
3.2. Results for the query ‘‘imatinib’’
Emphasis was given on innovative anti-leukemia drugs includ-
ing tyrosine kinase inhibitors (e.g. imatinib, dasatinib, nilotinib).
Imatinib was queried as the recognized prototype of these,
although MeSHy results were similar across queries. The develop-
ment of imatinib (trade name: Gleevec/Glivec) as an effective
agent capable of inducing cell apoptosis for the treatment of
patients suffering from chronic myelogenous leukemia (CML) rep-
resents an example of molecularly-targeted anticancer therapeu-
tics [34,35]. Imatinib is also used clinically for the treatment of
other tumors like gastrointestinal stromal tumor (GIST) by inhibit-
ing the c-kit kinase [36].
By querying the term ‘‘imatinib’’ in MeSHy on March 30, 2010, a
total number of 6401 articles found in PubMed were processed to
give 2496 pairs of MeSH terms (Fig. 3).
A ﬁrst noteworthy observation was the appearance of many
case reports within the top results, i.e. ﬁve different case reports
in the top 12 pairs. Case reports are generally considered an invalu-
able resource of new and unusual medical and pharmaceutical
information, with descriptions of single cases with unique features
that include previously unreported clinical conditions or unrecog-
nized disease symptoms, or even underestimated adverse drug
reactions [37]. Moreover, case reports are often the ﬁrst evidence
of innovative treatment, although clinical trials need to follow to
substantiate this [38]. Such knowledge is critical in advancing clin-
ical practice in a way that may lead to more rigorously designed
clinical studies and fundamental research by focusing on the
improvement of patient outcome.
By manually inspecting the ﬁrst two case reports associated
with the second and fourth pairs of MeSH terms (Fig. 3), a new per-
spective about the potential clinical use of imatinib was highly
ranked: ‘‘[. . .] patients with platelet-derived growth factor receptor
beta (PDGFRB) fusions genes are excellent candidates for treatment
with imatinib.’’ as quoted in Walz et al., [39] (article with the
Table 2
Representative query terms applied for the evaluation of MeSHy.
No. Representative query terms
1 Tyrosine kinase inhibitors: imatinib, erlotinib, geﬁtinib, nilotinib,
dasatinib, sorafenib, sunitinib, lapatinib, bafetinib, bosutinib
2 DNMT inhibitors: 5-azacytidine, 20-deoxy-5-azacytidine, zebularine
3 Retinoids and retinoid mimetics: ATRA, tamibarotene, bexarotene
4 Hybrid/Polar compounds and HDAC inhibitors: HMBA, SAHA
5 Bcl-2 inhibitors: oblimersen sodium, obatoclax mesylate
6 mTOR inhibitors: sirolimus, everolimus
7 Farnesyl transferase inhibitors: tipifarnib, lonafarnib
8 CDK inhibitors: ﬂavopiridol
924 T. Theodosiou et al. / Journal of Biomedical Informatics 44 (2011) 919–926second pair of MeSH terms) and ‘‘[. . .] PDGFRA fuses to diverse part-
ner genes in myeloid disorders. Identiﬁcation of these fusions is
important as they are particularly sensitive to imatinib [. . .]’’ as
quoted in Curtis et al. [40] (article with the fourth pair of MeSH
terms). PDGFRA and PDGFRB represent the two forms of the same
gene (PDGFR) [41]. Interestingly, both case reports were from the
same group of collaborators, corroborating the aforementioned
property of case reports to communicate rather unique and speciﬁc
knowledge, a property suited to MeSHy. Using the default PubMed
interface, such information could be found by reaching article num-
ber 1310 for the second MeSH term pair and article number 2578
for the fourth (Fig. 3). Otherwise, probably only a specialist working
within this ﬁeld of imatinib research would have been able to ex-
tract this information by querying PubMed directly with the spe-
ciﬁc terms ‘‘PDGFRB’’ and/or ‘‘PDGFRA’’ along with the general
one ‘‘imatinib’’, implying of course previous knowledge of this rela-
tionship. To this end, of particular interest to researchers working
within the imatinib ﬁeld could also be the ‘‘MYO18A protein, hu-
man’’ and ‘‘STRN protein, human’’ MeSH terms appearing in the sec-
ond and the fourth pairs respectively. This suggests their
involvement in the fusions with PDGFRB and PDGFRA; a suggestion
possibly worthy of further research. Such genetic information is
also new for both the underlying mechanisms of action of imatinib
and also its clinical usefulness, maybe prompting other research
groups to look at their clinical data for potential beneﬁts to patients.
On the other hand, MeSH terms already known to be related to
imatinib based on its main mechanism of action and its known
clinical effectiveness as deﬁned by regulatory authorities (Food
and Drug Administration, FDA; European Medicines Agency,
EMEA), such as ‘‘abl-bcr’’ (abl-bcr chimera kinase), and ‘‘chronic
myelogenous leukemia’’, are appearing among the 2496 MeSH
term pairs ranked relatively lower at 45 for ‘‘abl-bcr’’ and 627 for
‘‘leukemia myelogenous chronic’’. This further suggests the poten-
tial of MeSHy to focus on unanticipated information.
Importantly, several chemical MeSH terms were also included
in the results, which could be of particular interest to pharmaceu-
tical chemists. By linking such terms to biomedical knowledge, e.g.
disease pathogenesis, MeSHy could enrich their knowledge on
other disciplines and offer support and guidance to their work.
It is characteristic of the nature of the MeSHy results that all the
top ten pairs contain MeSH terms designated as ‘‘rare’’, based on
their ratio (1) within the queried articles (Fig. 3). Noteworthy is also
that almost all these top ten pairs of MeSH terms are found in pub-
lications ranked in PubMed with numbers greater than 306 among
the total of 6401 articles, despite being relatively, or very, recent.
Even a 2009 review is ranked 372nd meaning that the user would
have had to visit PubMed’s 19th results page (with the default 20
date-sorted results per page setting) to extract this information.
3.3. Results for the query ‘‘ﬂavonoids nutrition’’
The query ‘‘ﬂavonoids nutrition’’ was performed in MeSHy
(Fig. 4) in February 2011. High-ranking MeSH term pairs contained‘‘TOR Serine-Threonine Kinase’’, ‘‘Androgen Receptor Antagonists’’,
and ‘‘Topoisomerase I Inhibitors’’, terms which evaluators noted
were not immediately expected since they impinge on pharmacol-
ogy, medicine, drug targets and therapeutics. Therefore, MeSHy
could allow the user to infer that some ﬂavonoids in nutrients
may have therapeutic potential by targeting speciﬁc molecular tar-
gets within the cell – this is of course supported by the article con-
nected to the ﬁrst MeSH term pair (Fig. 4). In particular, the ability
of genistein combined polysaccharide (GCP) which is a nutritional
supplement mainly composed of the isoﬂavones genistein, daidz-
ein, and glycitein to inhibit cancer cell growth and modulate apop-
tosis through androgen receptor (AR) downregulation and mTOR
pro-apoptotic signal inhibition has been proposed in [42].4. Discussion
Our target while developing MeSHy was to build a transparent
method to facilitate knowledge discovery, an extremely compli-
cated process, by exploring existing high quality information in
PubMed in the form of manually assigned MeSH terms. We herein
support that we can approach such a target by pairing and statis-
tically analyzing MeSH terms, adding more weight to the notion
that combining information is a key factor in knowledge discovery
[43]. Signiﬁcantly, and to the best of our knowledge, MeSHy is the
ﬁrst publicly available tool for this speciﬁc task. In other words, we
believe the main contribution of this paper to be this novel and
complementary point of view of PubMed information, and not a
ubiquitous problem solver or competition to other excellent tools
in the ﬁeld. Overall, the results of the evaluations are promising,
but still very preliminary and based on informal pilot assessments,
suggesting the need for future rigorous studies to provide more
deﬁnitive conclusions.
MeSHy is able to process and present information from PubMed
queries in a way that unanticipated, initially at least, MeSH term
connections and the corresponding articles are shown to the user
ﬁrst, thus raising the possibility of discovering existing but ‘‘bur-
ied’’ information or generating novel knowledge. Consequently,
the re-organization of biomedical literature achieved by MeSHy
gives the opportunity to the user, e.g. curator or specialist, to fur-
ther impinge on the potential correlations and implications of spe-
ciﬁc pairs of MeSH terms through cycles of manual and automatic
analyses. The presentation of the broad MeSH term categories
(chemical and drugs, diseases, organisms, etc.) and their pairings,
further assists the user to understand the results better, to ﬁlter
and absorb only relevant information, while critically enabling in-
ter-disciplinary conclusions, e.g. by connecting diseases to agricul-
ture/nutrition. The positive comments from expert researchers in
diverse ﬁelds, who used MeSHy, and especially the included de-
tailed reports on the drug imatinib and on ﬂavonoids and nutrition,
are particularly encouraging – especially when considering the
complexity both of the pathophysiology of hematological diseases
and cancer, and of the molecular mechanisms underlying the phar-
macological action of drugs [33,44,45] and the actions of nutrition
supplements.
User feedback has also indicated that MeSHy could facilitate the
writing of review papers, since it has the capacity to indicate pop-
ular and expected knowledge and separate it from less supported,
unexpected, but potentially useful information – the reviewer can
then decide using his/her expertise what should be conferred to
the readership.
Although a direct comparison to other tools is difﬁcult, since the
internals of each method are different, as is the output format and
content, we also performed queries to the FACTA [25] and Epipha-
net [28] systems mentioned in the introduction. FACTA is a MED-
LINE search engine that produces ranked tables of concepts
T. Theodosiou et al. / Journal of Biomedical Informatics 44 (2011) 919–926 925relevant to the query. The concepts can be MeSH terms, gene
names, etc. in the title and the abstract of each PubMed document,
and they are ranked based on concurrence statistics, very similar to
the ones used in MeSHy. However, and contrary to MeSHy, only
single, i.e. not pairs of, concepts that co-occur with the query terms
are shown, whereas MeSHy calculates all pairs of all MeSH terms in
the returned documents. Also contrary to MeSHy, the concepts
which are ranked high are those expected to co-occur with the
query terms. Finally, for each concept, corresponding documents
are offered in a separate page and in date-order as per PubMed,
making an overview of the whole bibliography difﬁcult. In Epipha-
net the resulting information is not ranked, and neither are the
documents that support it. Most importantly however, neither sys-
tem directly and speciﬁcally promotes statistically unanticipated
information.
The main advantages of MeSHy could then be summarized as
follows:
1. Avoids using complicated and computationally-expensive Nat-
ural Language Processing techniques, like tokenization, stop-
word removal, stemming, text indexing, etc. Instead, MeSHy
only uses pre-assigned MeSH terms and their pre-calculated
frequencies (see 3 below).
2. Avoids using clustering and classiﬁcation models in order to
extract information from documents. It is fully unsupervised,
e.g. the user does not need to supply a training set, and does
not produce or use a mathematical model from training data.
The user only inputs a query which is used to retrieve relevant
documents from PubMed. After that there is no need for user
intervention. Furthermore, the lack of need for a training set
enables the discovery of novel relationships between biological
entities. A mathematical model based on such a (probably
biased) set could potentially be unable to identify novel and
unexpected knowledge.
3. Uses pre-calculated and manually curated high quality PubMed
information, i.e. MeSH term occurrences which are derived
from the MEDLINE Baseline Repository system. It combines
information by pairing MeSH terms, ranks MeSH term pairs,
and indirectly the documents themselves, based on a probabi-
listic score in a way that unanticipated MeSH term pairs are
ranked high. Thus, MeSHy helps users pinpoint new and inter-
esting pairs of MeSH terms that can be used in order to augment
their query. In general, MeSHy leverages a simple and widely
accessible resource (the robust and concise vocabulary of MeSH
terms in Medline citations) in a very innovative manner for
knowledge discovery.
The main limitation of MeSHy is in relation to MeSH terms.
MeSH terms are manually assigned to biomedical documents by
MEDLINE indexers and thus are subject to the perspective of each
indexer. Some indexers may use some MeSH terms more than oth-
ers when analyzing a document or they may use more general
MeSH terms than speciﬁc ones. Furthermore, indexers sometimes
assign irrelevant terms or miss relevant ones [46]. Moreover, the
use of MeSH terms could sometimes lead to loss of information,
since a whole document is represented as a limited set of manually
assigned terms. NLP techniques, although computationally com-
plex, when applied to full-text, if it is available, they could poten-
tially extract more and possibly better information. In the future
we plan to address the MeSH term limitations by statistically ana-
lyzing the occurrences and more generally the distribution of each
MeSH term in PubMed, in order to better understand their usage
patterns and improve the information MeSHy retrieves through
them.
Also, it is noteworthy that although the MESH term pairs in Me-
SHy are not created by chance, since only terms concurring in thesame document are paired, it is possible to have pairs without
meaning; at least from the perspective of the user (i.e. this can
be subjective). It should also be stressed that MeSHy is highly
dependent on the query as any other query-based system – e.g. a
poor query can retrieve irrelevant documents and thus insert noise
into MeSHy, or too few documents and thus make the use of Me-
SHy potentially irrelevant.
We are in the process of exploring the application of MeSHy on
pre-compiled and by-design more informative clusters of PubMed
documents; our previously published PuReD-MCL document clus-
tering algorithm [47] could provide such clusters. Finally, we plan
to investigate combining more than two MeSH terms again based
on concurrence in the same document and, perhaps more signiﬁ-
cantly, indirectly associate MeSH terms through graph analysis
methodologies.Funding
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